Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Model‐Based Drug–Drug Interaction Extrapolation Strategy From Adults to Children: Risdiplam in Pediatric Patients With Spinal Muscular Atrophy

Published:2021-09 Issue:6 Volume:110 Page:1547-1557
ISSN:0009-9236
Container-title:Clinical Pharmacology & Therapeutics
language:en
Short-container-title:Clin. Pharmacol. Ther.

Author:

Cleary Yumi¹²,Gertz Michael¹,Grimsey Paul³,Günther Andreas¹,Heinig Katja¹,Ogungbenro Kayode²,Aarons Leon²,Galetin Aleksandra²,Kletzl Heidemarie¹

Affiliation:

1. Roche Pharma Research and Early Development Pharmaceutical Sciences Roche Innovation Center Basel Switzerland

2. Centre for Applied Pharmacokinetic Research University of Manchester Manchester UK

3. Roche Pharma Research and Early Development Pharmaceutical Sciences Roche Innovation Center Welwyn UK

Funder

F. Hoffmann-La Roche

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpt.2384

Reference51 articles.

1. Spinal muscular atrophy

2. Identification and characterization of a spinal muscular atrophy-determining gene

3. Childhood spinal muscular atrophy: controversies and challenges

4. Discovery of Risdiplam, a Selective Survival of Motor Neuron-2 (SMN2) Gene Splicing Modifier for the Treatment of Spinal Muscular Atrophy (SMA)

5. Observational study of spinal muscular atrophy type I and implications for clinical trials

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pediatric Rare Diseases Development in the Pharmaceutical Industry: An International Consortium for Innovation and Quality in Pharmaceutical Development, Clinical Pharmacology Leadership Group‐Pediatrics Working Group, Rare Diseases Subteam Whitepaper Examining the Current Landscape and Recommendations for the Future;Clinical Pharmacology & Therapeutics;2024-08-15

2. Personalized metabolic whole-body models for newborns and infants predict growth and biomarkers of inherited metabolic diseases;Cell Metabolism;2024-08

3. PBPK Modeling of Entrectinib and Its Active Metabolite to Derive Dose Adjustments in Pediatric Populations Co‐Administered with CYP3A4 Inhibitors;Clinical Pharmacology & Therapeutics;2024-07-18

4. Combining data on the bioavailability of midazolam and physiologically‐based pharmacokinetic modeling to investigate intestinal CYP3A4 ontogeny;CPT: Pharmacometrics & Systems Pharmacology;2024-06-26

5. Dealing With Variable Drug Exposure Due to Variable Hepatic Metabolism: A Proof‐of‐Concept Application of Liquid Biopsy in Renal Impairment;Clinical Pharmacology & Therapeutics;2024-05-13

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3